rs1060500816
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_006231.4(POLE):c.4525A>G(p.Arg1509Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000452 in 1,461,466 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_006231.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 exome AF: 0.0000452 AC: 66AN: 1461466Hom.: 0 Cov.: 36 AF XY: 0.0000495 AC XY: 36AN XY: 726982
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
not provided Uncertain:2
This variant is denoted POLE c.4525A>G at the cDNA level, p.Arg1509Gly (R1509G) at the protein level, and results in the change of an Arginine to a Glycine (AGG>GGG). This variant has not, to our knowledge, been published in the literature as a pathogenic or benign germline variant. POLE Arg1509Gly was not observed in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether POLE Arg1509Gly is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 1509 of the POLE protein (p.Arg1509Gly). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 405708). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt POLE protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.R1509G variant (also known as c.4525A>G), located in coding exon 35 of the POLE gene, results from an A to G substitution at nucleotide position 4525. The arginine at codon 1509 is replaced by glycine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at